文献速递前列腺癌

前列腺切除术后放疗后血尿:发生率随长期随访增加

Hematuria following Post-Prostatectomy Radiotherapy: Incidence Increases with Long-Term Followup.
PubMed 文献 · J Urol · 2022-01-20

本研究为连续队列研究,纳入2007至2016年在本院接受前列腺切除术后放疗(PPRT)的216例男性,中位随访72个月,评估≥2级血尿的发生率、预测因素及对生活质量的影响。结果显示8年无≥2级血尿生存率为55%,抗凝/抗血小板治疗、膀胱V65 Gy≥43%及药物过敏与≥2级血尿相关,但血尿通常自限。

要点

  • PPRT后8年无≥2级血尿生存率为55%,血尿常见但多自限。
  • 抗凝/抗血小板治疗(HR 3.24)、膀胱V65 Gy≥43%(HR 1.97)及药物过敏(HR 1.73)与≥2级血尿相关。
  • 限制膀胱V65 Gy可能减少PPRT相关血尿。

核心结论

  • PPRT后血尿常见,尤其在药物过敏及抗凝/抗血小板治疗患者中,但PPRT相关血尿通常自限。
  • 限制膀胱V65 Gy可能减少PPRT相关血尿。

研究设计与样本

  • 连续队列研究,纳入2007至2016年在本院接受PPRT且潜在随访≥4年的216例男性。
  • PPRT中位剂量68.4 Gy(IQR 68.0-68.4),前列腺切除术后中位20个月(IQR 9-45)开始放疗,中位随访72个月(IQR 54-99)。

主要发现

  • 85例发生血尿,其中49例(58%)接受膀胱镜检查,13例(15%)需干预,26例(31%)出现复发性血尿。
  • 8年无≥2级血尿生存率为55%。
  • ≥2级血尿在抗凝/抗血小板治疗者中最高(HR 3.24,p<0.001),膀胱V65 Gy≥43%者(HR 1.97,p=0.004)及药物过敏者(HR 1.73,p=0.049)也与≥2级血尿相关。
  • 年龄<65岁(HR 0.81,p=0.374)及糖尿病(HR 0.49,p=0.098)与≥2级血尿无关。
  • 有无血尿患者间尿控领域评分变化(均值-3.5,95%CI:10.1,3.1)及刺激/梗阻领域评分变化(均值-3.0,95%CI:5.8,-0.3)未超过最小临床重要差值。

关键数值与推荐

  • ≥2级血尿定义为肉眼血尿。
  • 抗凝/抗血小板治疗者≥2级血尿风险HR 3.24(p<0.001)。
  • 膀胱V65 Gy≥43%者≥2级血尿风险HR 1.97(p=0.004)。
  • 药物过敏者≥2级血尿风险HR 1.73(p=0.049)。

临床怎么用

  • 作者认为限制膀胱V65 Gy可能减少PPRT相关血尿。
  • 原文未据此给出其他推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Hematuria following post-prostatectomy radiotherapy (PPRT) is inadequately characterized. We performed a consecutive cohort study of patients treated with PPRT at our institution to characterize this complication including impact on patient-reported quality of life. MATERIALS AND METHODS: Patients with potential followup ≥4 years following PPRT were identified. Freedom from ≥grade 2 hematuria (FFG2H; macroscopic blood) was estimated using the Kaplan-Meier method. Predictors of ≥grade 2 hematuria (G2H) were assessed via log-rank tests and the Cox model. Urinary patient-reported quality of life by EPIC-26 (26-question Expanded Prostate Cancer Index Composite) was compared for patients with/without hematuria using mixed-effects regression. RESULTS: A total of 216 men received PPRT (median 68.4 Gy, IQR 68.0-68.4) from 2007 to 2016 at a median of 20 months (IQR 9-45) after prostatectomy. Median followup was 72 months (IQR 54-99). A total of 85 men developed hematuria, of whom 49 (58%) underwent cystoscopy, 13 (15%) required intervention and 26 (31%) experienced recurrent hematuria. Eight-year FFG2H was 55%. G2H was highest in men treated with anticoagulation/antiplatelet therapy (HR 3.24, p <0.001), men with bladder V65 Gy ≥43% (HR 1.97, p=0.004) and men with medication allergies (HR 1.73, p=0.049). Age <65 years (HR 0.81, p=0.374) and diabetes mellitus (HR 0.49, p=0.098) were not associated with G2H. Change in urinary continence (mean -3.5, 95% CI: 10.1, 3.1) and irritation/obstruction (mean -3.0, 95% CI: 5.8, -0.3) domain scores did not exceed the minimally clinically important difference for men with/without hematuria. CONCLUSIONS: Hematuria following PPRT is common, especially among men with medication allergies and those on anticoagulation/antiplatelet therapy; however, PPRT-related hematuria is typically self-limited. Limiting bladder V65 Gy may reduce PPRT-related hematuria.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Turchan WT, Cutright D, Wu T, et al. Hematuria following Post-Prostatectomy Radiotherapy: Incidence Increases with Long-Term Followup. J Urol. 2022. PMID: 35050703. doi:10.1097/JU.0000000000002443

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。